ANDA 76392, held by Barr. Mefloquine Hydrochloride.
As of Nov 16, 2026, ANDA 76392 (Mefloquine Hydrochloride), held by Barr, was first approved by FDA on Dec 29, 2003, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae. Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 29, 2003 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mefloquine Hydrochloride250MG · tablet;oral | Mefloquine Hydrochloride | Rx |
| Oct 11, 2016 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 26, 2013 | Supplement 8Labeling · Standard review | Approved | |
| Sep 20, 2011 | Supplement 5Labeling | Approved | None posted |
| Nov 18, 2009 | Supplement 4Labeling | Approved | None posted |
| Jun 12, 2009 | Supplement 3Labeling | Approved | None posted |
| Dec 29, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters